Incyte (NASDAQ:INCY) Announces Quarterly Earnings Results

Incyte (NASDAQ:INCY) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16), FiscalAI reports. Incyte had a return on equity of 26.56% and a net margin of 24.69%.The company had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.35 billion. During the same period in the prior year, the firm earned $1.43 EPS. Incyte’s quarterly revenue was up 27.8% on a year-over-year basis.

Incyte Trading Up 0.6%

NASDAQ:INCY opened at $109.03 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.20 and a quick ratio of 3.13. The business’s 50-day simple moving average is $101.83 and its 200-day simple moving average is $93.57. Incyte has a fifty-two week low of $53.56 and a fifty-two week high of $112.29. The stock has a market capitalization of $21.40 billion, a PE ratio of 18.26, a price-to-earnings-growth ratio of 0.65 and a beta of 0.82.

Key Headlines Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q4 revenue and net income surprised to the upside — revenue of $1.51B beat consensus (~$1.35B) and the company reported higher net for the quarter, which supports near-term cash flow and valuation metrics. MarketWatch: Incyte 4Q Net Up on Higher Revenue
• Neutral Sentiment: Analyst & media previews highlight Incyte as a value play and focus attention on the pipeline as the key to reducing Jakafi reliance; these are longer‑term considerations that could moderate risk if clinical/readouts progress. Investing.com: Can pipeline ease Jakafi reliance?
• Negative Sentiment: Management issued a weak 2026 revenue forecast below Street estimates and said Opzelura is expected to underperform, heightening worry about its ability to replace revenue from Jakafi ahead of patent losses — a key driver of the stock decline after the print. Reuters: Incyte weak 2026 revenue forecast
• Negative Sentiment: EPS missed consensus ($1.80 vs. $1.96 expected) despite the revenue beat, signaling margin/expense pressure and amplifying near-term uncertainty; investors will watch guidance, Opzelura uptake, and Jakafi exclusivity developments closely. Incyte Q4 press release / slides

Insider Transactions at Incyte

In other Incyte news, EVP Steven H. Stein sold 20,105 shares of Incyte stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $102.51, for a total value of $2,060,963.55. Following the sale, the executive vice president directly owned 63,129 shares in the company, valued at approximately $6,471,353.79. The trade was a 24.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael James Morrissey sold 4,323 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $97.26, for a total transaction of $420,454.98. Following the completion of the transaction, the executive vice president owned 27,507 shares in the company, valued at approximately $2,675,330.82. This represents a 13.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 95,225 shares of company stock valued at $9,519,745. 17.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Incyte

Several hedge funds and other institutional investors have recently modified their holdings of INCY. MUFG Securities EMEA plc bought a new stake in shares of Incyte during the second quarter worth about $32,000. CYBER HORNET ETFs LLC acquired a new stake in Incyte during the 2nd quarter worth about $33,000. Geneos Wealth Management Inc. increased its holdings in Incyte by 350.0% in the first quarter. Geneos Wealth Management Inc. now owns 756 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 588 shares in the last quarter. CIBC Private Wealth Group LLC grew its position in shares of Incyte by 153.8% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 726 shares of the biopharmaceutical company’s stock worth $62,000 after buying an additional 440 shares during the period. Finally, Brown Brothers Harriman & Co. boosted its stake in Incyte by 43.5% during the third quarter. Brown Brothers Harriman & Co. now owns 818 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 248 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. The Goldman Sachs Group restated a “neutral” rating and issued a $90.00 price objective on shares of Incyte in a research note on Thursday, January 8th. Mizuho set a $121.00 price target on shares of Incyte and gave the stock an “outperform” rating in a research report on Monday, December 8th. TD Cowen restated a “buy” rating on shares of Incyte in a report on Tuesday, January 13th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $107.00 target price (down previously from $116.00) on shares of Incyte in a research note on Tuesday, January 20th. Finally, Barclays lifted their target price on Incyte from $115.00 to $116.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Nine analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $103.29.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.